Ovarian Cancer: Surgery, Recurrence & New Treatment Options

FIGO stage describes spread: disease confined to the ovaries or tubes, pelvic extension, disease beyond the pelvis or regional nodes, and distant spread. Extensive disease on abdominal surfaces is not automatically the same as distant organ metastasis. Imaging, surgical findings and pathology are interpreted together.

A gynecologic oncologist should assess whether initial surgery can achieve complete visible tumor removal with acceptable risk. If that is unlikely, or surgical risk is high, chemotherapy first may be appropriate, followed by interval surgery when response and fitness allow. This sequence is an active treatment strategy, not an abandonment of surgery.

Ask about possible bowel procedures, a stoma, fertility and recovery before consenting to an operation. HIPEC is considered only in selected settings and centers; it is not a universal addition for every stage or recurrence.

• Germline testing looks for inherited susceptibility, even when family history is not obvious. A tumor BRCA result may require germline confirmation and genetic counseling for its implications for relatives.
• HRD describes impaired homologous recombination repair. It is broader than BRCA mutation; the assay and clinical setting matter. HRD positivity does not mean every PARP drug is suitable at every recurrence.
• FRα expression can select an antibody–drug conjugate; PD-L1 CPS can select a specific immunotherapy combination. These are different protein-based tests, not substitutes for BRCA or HRD.
• KRAS testing is particularly relevant to certain recurrent low-grade serous treatments. MMR/MSI testing can matter for selected histologies, inherited-risk assessment or treatment pathways.

For many advanced epithelial cancers, treatment combines cytoreductive surgery with carboplatin and paclitaxel; bevacizumab may be incorporated for selected patients. Maintenance aims to prolong control after a response. It is a separate decision from choosing treatment for cancer that is actively progressing.

Current US olaparib first-line maintenance applies to qualifying BRCA-mutated advanced disease responding to platinum; its combination with bevacizumab uses an HRD-positive indication. Current US niraparib first-line maintenance is also restricted to HRD-positive advanced disease responding to platinum. Older statements that US niraparib maintenance is available regardless of HRD should not guide present decisions.

Recurrent-disease maintenance has its own gene and prior-treatment requirements. Review previous PARP exposure, blood counts, blood pressure where relevant, side effects and the local label. Persistent cytopenias need assessment, including the uncommon risk of marrow disorders.

Review the interval from platinum, the depth and duration of the previous response, residual toxicity and all intervening treatments. A six-month interval is a familiar classification aid, but does not capture every aspect of platinum suitability. Repeat surgery is appropriate only for carefully selected recurrence; control of symptoms and preserving function remain central.

Selected US options for platinum-resistant disease

• Mirvetuximab soravtansine (Elahere): FRα-positive adult epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three systemic regimens, using the required test. Eye examinations and preventive eye care are integral because ocular toxicity can be significant.
• Pembrolizumab with paclitaxel, with or without bevacizumab: adult disease with PD-L1 CPS ≥1 after one or two prior systemic regimens, using an FDA-authorized test. This is a defined combination, not unrestricted immunotherapy for ovarian cancer.
• Relacorilant with nab-paclitaxel: adult disease after one to three systemic regimens, at least one including bevacizumab. This glucocorticoid-receptor antagonist requires review of steroid use, interactions, infection and adrenal-related risks.

These indications apply to the named populations and region. The best next choice depends on prior exposure, tumor findings, bowel involvement, health and preferences; comparing headline response rates across unrelated trials is not a reliable ranking method.

Low-grade serous cancer often behaves and responds differently from high-grade serous cancer. Surgical assessment, endocrine therapy and MAPK-pathway treatment may have distinct roles. Expert pathology review is particularly valuable when the diagnosis or a previous borderline tumor is unclear.

In the US, avutometinib plus defactinib has accelerated approval for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy. The approval is based on response and response duration, with confirmatory benefit still required. This is not an indication for all ovarian cancers or every KRAS finding. Eye, skin, muscle and liver effects require monitoring.

CLDN6-directed CAR-T cells, with or without an RNA vaccine intended to amplify those cells, have been studied in early human trials including selected ovarian cancers. The published BNT211-01 phase I report involved mixed solid tumors and focused on safety and dose finding. It does not establish a routine ovarian treatment or show that an RNA vaccine alone has the same effect.

For any study, confirm the exact histology, target-expression assay, previous-treatment rules, participating center and current recruitment directly with the trial team before arranging travel.

Fudan University Shanghai Cancer Center · Shanghai, China

Its gynecologic team offers ovarian cancer care across the treatment course, including complex tumor-reduction surgery. Ask about likely residual disease and possible bowel procedures.

MD Anderson Cancer Center · Houston, United States

Combines gynecologic cancer care with clinical research. A specialist review can compare standard treatment, fertility priorities and relevant study screening.

Memorial Sloan Kettering Cancer Center · New York, United States

Offers cytoreductive surgery and selected fertility-preserving approaches. The surgical review focuses on removing visible disease while planning the extent and recovery burden of the operation.

This guide mainly covers epithelial cancers of the ovary, fallopian tube and peritoneum, which share many staging and treatment principles. Germ-cell tumors, sex-cord stromal tumors and borderline tumors require different pathways and should not automatically receive the same plan.

Persistent bloating, early fullness, pelvic or abdominal pain, urinary changes or increasing abdominal size deserve assessment, especially when new and frequent. These symptoms have many noncancer causes. Family history, BRCA-related susceptibility and some other inherited syndromes can increase risk.

Ultrasound and CT help assess an adnexal mass and disease extent. Tissue examination confirms the diagnosis; the team chooses a safe route to obtain it, particularly before chemotherapy. CA-125 can support monitoring but may rise with benign conditions and may remain normal in some cancers. CA-125 and ultrasound have not established an effective routine screening strategy for average-risk people.

Ascites can worsen fullness, breathlessness and appetite; discuss whether drainage or cancer treatment can relieve it. Persistent vomiting, marked distension, severe abdominal pain or inability to pass stool or gas needs prompt assessment for bowel obstruction. Do not simply add fiber or laxatives without checking the cause.

After surgery and chemotherapy, care may need to address neuropathy, bowel or stoma function, surgical menopause, sexual health and fatigue. Fertility preservation is restricted to appropriate tumor types and stages; raise this before treatment. Nutrition and activity plans should match bowel function and recovery rather than a generic anticancer diet.

Agree on how symptoms, examinations, CA-125 and imaging will be used. An isolated CA-125 rise should prompt discussion, not an automatic change of chemotherapy: a randomized trial did not show a survival benefit from starting chemotherapy solely because the marker rose before clinical recurrence. Modern treatment history and eligibility for selected local treatment also need consideration.

• Bring full pathology, operative notes and the amount and location of residual disease.
• List all platinum, bevacizumab, PARP, immunotherapy and ADC exposure, with response and stopping reasons.
• Include germline/tumor BRCA, HRD, FRα and any other relevant reports, with original imaging and CA-125 trends.
• Ask what finding changes the next choice, whether a further operation is realistic, and what benefit and daily burden to expect.